2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1506

Total Hip Replacement Outcomes in Ankylosing Spondylitis
Abstract Number: 2120

Total Knee Replacement Outcomes In Patients With Psoriatic Arthritis, Osteoarthritis With Cutaneous Psoriasis, and Osteoarthritis
Abstract Number: 2793

Towards Developing a Rheumatology-Specific Transition Of Care Program
Abstract Number: 1228

Trabecular BONE Score In Rheumatoid Arthritis and Ankylosing Spondylitis and Changes During LONG TERM Treatment With TNFA Blocking Agents
Abstract Number: 366

Traditional Cardiac Risk Factors Predict Significant Coronary Plaque Burden In Asymptomatic Patients With Rheumatoid Arthritis
Abstract Number: 2754

Trajectory Of Cartilage Thickness Change During The Years Prior To Knee Replacement: Data From The Osteoarthritis Initiative
Abstract Number: 459

Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
Abstract Number: 645

Transcript Profiling Of Blood and Kidney Biopsies From Chinese Patients With Lupus Nephritis Reveals Concordant Activation Of Type I IFN Signaling In The Blood and Kidney, Reduced B Cell Presence In The Blood, and Increased Macrophages In The Kidney
Abstract Number: 172

Transcript Profiling Of Kidney Biopsies From Chinese Patients With Lupus Nephritis Suggests a Prevalence Of Infiltrating CD8+ T Cells, Monocytes/Macrophages, and B Cells In ISN/RPS Class IV Disease
Abstract Number: 1631

Transcription Activation-Like Effector Nuclease-Mediated Enhancer Knockout Influences TNFAIP3 Gene Expression and Mimics a Functional Phenotype Associated With Systemic Lupus Erythematosus
Abstract Number: 2699

Transcription Factor RFX1 Regulates Th17 Differentiation and Its Role In The Pathogenesis Of Systemic Lupus Erythematosus
Abstract Number: 1888

Transcriptional Regulation Of Peptidylarginine Deiminase Type IV: Implications For Rheumatoid Arthritis
Abstract Number: 159

Transcriptomic Blood Markers and Molecular Stratification In Sarcoidosis
Abstract Number: 2209

Transition From The Pediatric Rheumatologist To The Adult Rheumatologist: Outcomes Of 5 Years Of Experience Between Two Institutions
Abstract Number: 1391

Transporters As Drug Gateway Into The Cell For Specific Targeting Of Tyrosine Kinase Signaling Pathway In Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].